The combination of zalfermin and semaglutide has additive therapeutic effects in a diet-induced obese and biopsy-confirmed mouse model of MASH

• Jenny Norlin ,

  Contributed equally to this work with: Jenny Norlin, Maria Dermit

  Roles Conceptualization, Formal analysis, Writing – review & editing

  Affiliation Global Drug Discovery, Novo Nordisk, Maaloev, Denmark

  ⨯
• Maria Dermit ,

  Contributed equally to this work with: Jenny Norlin, Maria Dermit

  Roles Formal analysis, Writing – review & editing

  Affiliation AI & Digital Research, Research & Early Development, Novo Nordisk Research Centre, Oxford, United Kingdom

  https://orcid.org/0000-0002-6287-8367

  ⨯
• Nikos Sidiropoulos,

  Roles Formal analysis

  Affiliation Global Drug Discovery, Novo Nordisk, Maaloev, Denmark

  ⨯
• Elisabeth D. Galsgaard,

  Roles Conceptualization, Formal analysis

  Affiliation Global Drug Discovery, Novo Nordisk, Maaloev, Denmark

  ⨯
• Henrik H. Hansen,

  Roles Writing – review & editing

  Affiliation Gubra, Hørsholm, Denmark

  ⨯
• Michael Feigh,

  Roles Conceptualization

  Affiliation Gubra, Hørsholm, Denmark

  ⨯
• Sanne S. Veidal,

  Roles Conceptualization, Formal analysis

  Affiliation Global Drug Discovery, Novo Nordisk, Maaloev, Denmark

  ⨯
• Markus Latta,

  Roles Conceptualization, Formal analysis

  Affiliation Global Drug Discovery, Novo Nordisk, Maaloev, Denmark

  ⨯
• Emma Henriksson,

  Roles Conceptualization, Formal analysis, Writing – review & editing

  Affiliation Global Drug Discovery, Novo Nordisk, Maaloev, Denmark

  ⨯
• Birgitte Andersen

  Roles Conceptualization, Formal analysis, Writing – review & editing

  * E-mail: btta@novonordisk.com

  Affiliation Global Drug Discovery, Novo Nordisk, Maaloev, Denmark

  https://orcid.org/0000-0003-1423-6797

  ⨯